[[[[(2R,3S,4R,5R)-5-(2-氨基-6-氧代-3H-嘌呤-9-基)-3,4-二羟基四氢呋喃-2-基]甲氧基-羟基磷酰]氧基-羟基磷酰]氨基]膦酸 | 34273-04-6

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 中文名称: [[[[(2R,3S,4R,5R)-5-(2-氨基-6-氧代-3H-嘌呤-9-基)-3,4-二羟基四氢呋喃-2-基]甲氧基-羟基磷酰]氧基-羟基磷酰]氨基]膦酸
• 英文名称: 5'-guanylylimidodiphosphate
• 英文别名: Guanylyl Imidodiphosphate；[[[[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid
• CAS: 34273-04-6
• 化学式: C₁₀H₁₇N₆O₁₃P₃
• 分子量: 522.199
• InChiKey: UQABYHGXWYXDTK-UUOKFMHZSA-N

物化性质

• 密度：
  2.77±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -6.8
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  298
• 氢给体数：
  9
• 氢受体数：
  15

反应信息

• 作为反应物：
  描述：

  [[[[(2R,3S,4R,5R)-5-(2-氨基-6-氧代-3H-嘌呤-9-基)-3,4-二羟基四氢呋喃-2-基]甲氧基-羟基磷酰]氧基-羟基磷酰]氨基]膦酸 、 lysyl adenylate 在 zinc(II) chloride 作用下， 以31%的产率得到adenosine(guanosine) 5',5'''-P¹,P⁴-(β,γ-imido)tetraphosphate
  参考文献：
  名称：

  Characterisation of stress protein LysU. Enzymic synthesis of diadenosine 5′,5‴-P¹,P⁴-tetraphosphate (Ap₄A) analogues by LysU

  摘要：

  The stress protein LysU (lysyl tRNA synthetase) has been purified from a recombinant strain of Escherichia coli expressing the plasmid pXLys5, and kinetically characterised. Preparative syntheses of analogues of the biologically important molecule diadenosine 5',5'''-P-1,P-4-tetraphosphate (Ap(4)A) are then achieved in good yield by enzyme catalysis, using purified LysU.

  DOI：

  10.1039/p19960002009

文献信息

• [EN] COMPOSITIONS AND METHODS FOR TREATING CANCER<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DU CANCER
  申请人：UNIV CALIFORNIA

  公开号：WO2018112420A1

  公开（公告）日：2018-06-21

  Disclosed herein, inter alia, are compositions and methods for modulating Ras and treating cancer.

  本文披露了用于调节Ras和治疗癌症的组合物和方法。
• Compositions and methods for treating cancer
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US11136297B2

  公开（公告）日：2021-10-05

  Disclosed herein, inter alia, are compositions and methods for modulating Ras and treating cancer.

  本申请 disclosure 还包括以下内容：用以调控 Ras 和治疗癌症的化合物和方法。
• Method of treating edematous retinal disorders
  申请人：——

  公开号：US20030186917A1

  公开（公告）日：2003-10-02

  The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from the subretinal and retinal spaces and thereby reduce the accumulation of said fluid associated with retinal detachment and retinal edema. The P2Y receptor agonist can be administered with therapeutic and adjuvant agents commonly used to treat edematous retinal disorders. The pharmaceutical formulation useful in this invention comprises a P2Y receptor agonist with enhanced resistance to extracellular hydrolysis, such as dinucleoside polyphosphate compounds, or hydrolysis-resistant mononucleoside triphosphates.

  本发明提供了一种治疗水肿性视网膜疾病的方法。该方法包括施用包含抗水解 P2Y 受体激动剂的药物制剂，以刺激从视网膜下和视网膜间隙清除病理性外来液体，从而减少与视网膜脱离和视网膜水肿相关的上述液体的积聚。P2Y 受体激动剂可与常用于治疗水肿性视网膜疾病的治疗剂和辅助剂一起使用。本发明中有用的药物制剂包括抗细胞外水解能力增强的 P2Y 受体激动剂，如二核苷多磷酸盐化合物或抗水解的单核苷三磷酸盐。
• Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
  申请人：Yerxa R. Benjamin

  公开号：US20050085439A1

  公开（公告）日：2005-04-21

  The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from the subretinal and retinal spaces and thereby reduce the accumulation of said fluid associated with retinal detachment and retinal edema. The P2Y receptor agonist can be administered with therapeutic and adjuvant agents commonly used to treat edematous retinal disorders. The pharmaceutical formulation useful in this invention comprises a P2Y receptor agonist with enhanced resistance to extracellular hydrolysis, such as dinucleoside polyphosphate compounds, or hydrolysis-resistant mononucleoside triphosphate salts. The present invention also provides P 1 -(2′-deoxycytidine 5′-)P 4 -(uridine 5′-)tetraphosphate, tetra-(alkali metal) salts such as tetrasodium, tetralithium, tetrapotassium, and mixed (tetra-alkali metal) salts. The present further provides a pharmaceutical formulation comprising a P 1 -(2′-deoxycytidine 5′-)P 4 -(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, in a pharmaceutically acceptable carrier.

  本发明提供了一种治疗水肿性视网膜疾病的方法。该方法包括施用包含抗水解 P2Y 受体激动剂的药物制剂，以刺激从视网膜下和视网膜间隙清除病理性外来液体，从而减少与视网膜脱离和视网膜水肿相关的上述液体的积聚。P2Y 受体激动剂可与常用于治疗水肿性视网膜疾病的治疗剂和辅助剂一起使用。本发明中有用的药物制剂包括具有增强的抗细胞外水解能力的 P2Y 受体激动剂，如二核苷多磷酸化合物或抗水解的单核苷三磷酸盐。本发明还提供了 P 1 -(2′-脱氧胞苷 5′-)P 4 -(尿苷 5′-)四磷酸，四(碱金属)盐，如四钠、四锂、四钾和混合(四碱金属)盐。本发明进一步提供了一种药物制剂，其中包含 P 1 -(2′-脱氧胞苷 5′-)P 4 -(尿苷-5′-)四磷酸四碱金属盐，以及药学上可接受的载体。
• COMPOSITIONS AND METHODS FOR TREATING CANCER
  申请人：The Regents of the University of California

  公开号：EP3555077A1

  公开（公告）日：2019-10-23